Table 2.
Follow-up outcomes of young adult patients with ESRD according to their use of statins.
| Statin Users | Nonstatin Users | Statin Users vs. Nonstatin Users | |||||
|---|---|---|---|---|---|---|---|
| No. of Event | Person-Years | Incidence Rate | No. of Event | Person-Years | Incidence Rate | SHR/HR (95%CI); p Value | |
| MACCE a | 87 | 3263.61 | 2.65 (2.09–3.21) | 138 | 9608.12 | 1.44 (1.20–1.68) | 1.87 (1.43–2.45); <0.0001 |
| AMI | 51 | 3376.31 | 1.51 (1.09–1.92) | 30 | 9940.81 | 0.30 (0.19–0.41) | 5.34 (3.40–8.39); <0.0001 |
| Stroke | 16 | 3475.96 | 0.46 (0.24–0.69) | 68 | 9815.81 | 0.70 (0.53–0.86) | 0.66 (0.39–1.14); 0.1368 |
| CV death | 8 | 3524.99 | 0.23 (0.10–0.44) | 17 | 10,025.6 | 0.17 (0.09–0.25) | 1.33 (0.57–3.08); 0.5132 |
| All-cause mortality | 69 | 3524.99 | 1.96 (1.50–2.42) | 229 | 10,025.6 | 2.28 (1.99–2.58) | 0.87 (0.66–1.14); 0.3058 |
a: Any of myocardial infarction, cardiogenic shock, new-onset heart failure, malignant arrhythmia, and cerebrovascular events; AMI: acute myocardial infarction; CI: confidence interval; CV: cardiovascular; HR: hazard ratio; SHR: subdistribution hazard ratio.